BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 23285843)

  • 1. [Phase III clinical trial of brimonidine in patients with primary open-angle glaucoma and ocular hypertension--comparison of the effects of brimonidine monotherapy versus timolol monotherapy, or combination brimonidine/prostaglandins therapy versus combination placebo/prostaglandins therapy].
    Araie M; Yamazaki Y; Sugiyama K; Kuwayama Y; Tanihara H
    Nippon Ganka Gakkai Zasshi; 2012 Oct; 116(10):955-66. PubMed ID: 23285843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fixed-combination brimonidine-timolol versus latanoprost in glaucoma and ocular hypertension: a 12-week, randomized, comparison study.
    Katz LJ; Rauchman SH; Cottingham AJ; Simmons ST; Williams JM; Schiffman RM; Hollander DA
    Curr Med Res Opin; 2012 May; 28(5):781-8. PubMed ID: 22458918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial.
    Sherwood MB; Craven ER; Chou C; DuBiner HB; Batoosingh AL; Schiffman RM; Whitcup SM
    Arch Ophthalmol; 2006 Sep; 124(9):1230-8. PubMed ID: 16966616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dorzolamide/timolol combination versus concomitant administration of brimonidine and timolol: six-month comparison of efficacy and tolerability.
    Sall KN; Greff LJ; Johnson-Pratt LR; DeLucca PT; Polis AB; Kolodny AH; Fletcher CA; Cassel DA; Boyle DR; Skobieranda F
    Ophthalmology; 2003 Mar; 110(3):615-24. PubMed ID: 12623832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Three-month, randomized, parallel-group comparison of brimonidine-timolol versus dorzolamide-timolol fixed-combination therapy.
    Nixon DR; Yan DB; Chartrand JP; Piemontesi RL; Simonyi S; Hollander DA
    Curr Med Res Opin; 2009 Jul; 25(7):1645-53. PubMed ID: 19476406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 12-week study comparing the fixed combination of brimonidine and timolol with concomitant use of the individual components in patients with glaucoma and ocular hypertension.
    Goñi FJ;
    Eur J Ophthalmol; 2005; 15(5):581-90. PubMed ID: 16167288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of latanoprost, brimonidine, and a fixed combination of timolol and dorzolamide on circadian intraocular pressure in patients with glaucoma or ocular hypertension.
    Orzalesi N; Rossetti L; Bottoli A; Fumagalli E; Fogagnolo P
    Arch Ophthalmol; 2003 Apr; 121(4):453-7. PubMed ID: 12695241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A double-masked randomized crossover study comparing the effect of latanoprost/timolol and brimonidine/timolol fixed combination on intraocular pressure and ocular blood flow in patients with primary open-angle glaucoma or ocular hypertension.
    Hommer A; Sperl P; Resch H; Popa-Cherecheanu A; Qiao C; Schmetterer L; Garhöfer G
    J Ocul Pharmacol Ther; 2012 Dec; 28(6):569-75. PubMed ID: 22775229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Twice-daily brinzolamide/brimonidine fixed combination versus brinzolamide or brimonidine in open-angle glaucoma or ocular hypertension.
    Aung T; Laganovska G; Hernandez Paredes TJ; Branch JD; Tsorbatzoglou A; Goldberg I
    Ophthalmology; 2014 Dec; 121(12):2348-55. PubMed ID: 25064721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the efficacy and safety of dorzolamide 2% when added to brimonidine 0.2% or timolol maleate 0.5% in patients with primary open-angle glaucoma.
    Oztürk F; Ermiş SS; Inan UU; Aşagidag A; Yaman S
    J Ocul Pharmacol Ther; 2005 Feb; 21(1):68-74. PubMed ID: 15718830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An eight-week, multicentric, randomized, interventional, open-label, phase 4, parallel comparison of the efficacy and tolerability of the fixed combination of timolol maleate 0.5%/brimonidine tartrate 0.2% versus fixed combination of timolol maleate 0.5%/dorzolamide 2% in patients with elevated intraocular pressure.
    Hatanaka M; Grigera DE; Barbosa WL; Jordao M; Susanna R
    J Glaucoma; 2008 Dec; 17(8):674-9. PubMed ID: 19092465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brimonidine and timolol fixed-combination therapy versus monotherapy: a 3-month randomized trial in patients with glaucoma or ocular hypertension.
    Craven ER; Walters TR; Williams R; Chou C; Cheetham JK; Schiffman R;
    J Ocul Pharmacol Ther; 2005 Aug; 21(4):337-48. PubMed ID: 16117698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dorzolamide/Timolol fixed combination versus concomitant administration of brimonidine and timolol in patients with elevated intraocular pressure: a 3-month comparison of efficacy, tolerability, and patient-reported measures.
    Solish AM; DeLucca PT; Cassel DA; Kolodny AH; Hustad CM; Skobieranda F
    J Glaucoma; 2004 Apr; 13(2):149-57. PubMed ID: 15097262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Topical brimonidine 0.2%/timolol 0.5% ophthalmic solution: in glaucoma and ocular hypertension.
    Frampton JE
    Drugs Aging; 2006; 23(9):753-61. PubMed ID: 17020399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of systemic beta-blocker therapy on the efficacy and safety of topical brimonidine and timolol. Brimonidine Study Groups 1 and 2.
    Schuman JS
    Ophthalmology; 2000 Jun; 107(6):1171-7. PubMed ID: 10857839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Three-month randomized trial of fixed-combination brinzolamide, 1%, and brimonidine, 0.2%.
    Katz G; Dubiner H; Samples J; Vold S; Sall K
    JAMA Ophthalmol; 2013 Jun; 131(6):724-30. PubMed ID: 23579344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0:005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension.
    Franks WA; Renard JP; Cunliffe IA; Rojanapongpun P
    Clin Ther; 2006 Mar; 28(3):332-9. PubMed ID: 16750448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of 24-hour intraocular pressure reduction obtained with brinzolamide/timolol or brimonidine/timolol fixed-combination adjunctive to travoprost therapy.
    Konstas AG; Holló G; Haidich AB; Mikropoulos DG; Giannopoulos T; Voudouragkaki IC; Paschalinou E; Konidaris V; Samples JR
    J Ocul Pharmacol Ther; 2013 Sep; 29(7):652-7. PubMed ID: 23550916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of ocular hypotensive actions of fixed combinations of brimonidine/timolol and dorzolamide/timolol.
    García-Feijoó J; Sáenz-Francés F; Martínez-de-la-Casa JM; Méndez-Hernández C; Fernández-Vidal A; Calvo-González C; García-Sánchez J
    Curr Med Res Opin; 2010 Jul; 26(7):1599-606. PubMed ID: 20429818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, investigator-masked, 4-week study comparing timolol maleate 0.5%, brinzolamide 1%, and brimonidine tartrate 0.2% as adjunctive therapies to travoprost 0.004% in adults with primary open-angle glaucoma or ocular hypertension.
    Reis R; Queiroz CF; Santos LC; Avila MP; Magacho L
    Clin Ther; 2006 Apr; 28(4):552-9. PubMed ID: 16750466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.